Status:
NOT_YET_RECRUITING
Prolonged Hypercoagulability Following Major Liver Resection for Malignancy
Lead Sponsor:
Western University, Canada
Collaborating Sponsors:
Valeo Pharma Inc
Conditions:
Hepatic Disease
Surgery-Complications
Eligibility:
All Genders
18+ years
Phase:
PHASE3
Brief Summary
This clinical trial will investigate the ability of thromboelastrogrpahy (TEG®) to detect hypercoagulability after liver surgery and will examine the effect of extended thromboprophylaxis (medical tre...
Eligibility Criteria
Inclusion
- Adults aged 18 years or older at the time of enrollment.
- Requiring major liver resection (\>2 liver sections) for any oncologic indication.
- Requiring postoperative thromboprophylaxis will be included.
- Willing and able to perform subcutaneous injections according to the study protocol, or receive injections form a caregiver delegated by the participant.
Exclusion
- Anyone below 18 years of age.
- Patients on current anticoagulant and/or antiplatelet therapy
- Patients with a history of thrombotic events
- Patients with a coagulation disorder.
- Patients with recognized thrombophilia.
- Patients who cannot understand/speak or read in English.
Key Trial Info
Start Date :
June 1 2024
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
February 1 2028
Estimated Enrollment :
50 Patients enrolled
Trial Details
Trial ID
NCT06153394
Start Date
June 1 2024
End Date
February 1 2028
Last Update
April 23 2024
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
London Health Sciences Centre
London, Ontario, Canada, N6A 5A5